Abstract
Background Genetic scores may provide an objective measure of a man’s risk of prostate cancer and thus inform screening decisions. We evaluated whether a polygenic hazard score based on 290 genetic variants (PHS290) is associated with risk of prostate cancer in a diverse population, including Black men, who have higher average risk of prostate cancer death but are often treated as a homogeneous, high-risk group
Methods This was a retrospective analysis of Million Veteran Program (MVP), a national, population-based cohort study of United States military veterans conducted 2011-2021. Cox proportional hazards analyses tested for association of genetic and other risk factors (including self-reported race/ethnicity and family history) with age at death from prostate cancer, age at diagnosis of metastatic (nodal or distant) prostate cancer, and age at diagnosis of any prostate cancer.
Results 590,750 male participants were included. Median age at last follow-up was 69 years. PHS290 was associated with fatal prostate cancer in the full cohort and for each racial/ethnic group (p<10−10). Comparing men in the highest 20% of PHS290 to those in the lowest 20%, the hazard ratio for fatal prostate cancer was 4.42 [95% CI: 3.91-5.02]. When accounting for guideline-recommended risk factors (family history, race/ethnicity), PHS290 remained the strongest independent predictor of any, metastatic, and fatal prostate cancer.
Conclusions PHS290 stratified US veterans of diverse ancestry for lifetime risk of prostate cancer, including metastatic and fatal cancer. Predicting genetic risk of lethal prostate cancer with PHS290 might inform individualized decisions about prostate cancer screening.
Competing Interest Statement
TMS reports honoraria from Varian Medical Systems and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board; he has received in-kind research support from GE Healthcare via a research agreement with the University of California San Diego. These companies might potentially benefit from the research results. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.
Funding Statement
This research used data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration. This research was supported by the Million Veteran Program MVP022 award # I01 CX001727 (PI: Richard L. Hauger MD). This publication does not represent the views of the Department of Veterans Affairs or the United States Government. Dr. Hauger was additionally funded by the VISN-22 VA Center of Excellence for Stress and Mental Health (CESAMH) and National Institute of Aging RO1 grant AG050595 (The VETSA Longitudinal Twin Study of Cognition and Aging VETSA 4). This research was supported by VA MVP022. Meghana S. Pagadala was supported by the National Institutes of Health (#1F30CA247168, #T32CA067754). Tyler Seibert and Roshan Karunamuni were supported by the National Institutes of Health (NIH/NIBIB #K08EB026503), the Prostate Cancer Foundation, and the University of California (#C21CR2060).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
VA Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Additional analysis and figures.
Data Availability
Requests regarding data access may be directed to MVPLOI@va.gov
